MedTrace Logo

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

NCT06389526 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-09-19

No results posted yet for this study

Summary

The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL

CHS-1000

Specified dose on specified days

BIOLOGICAL

Toripalimab

Specified dose on specified days

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-15
Primary Completion
2028-05-30
Completion
2028-05-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06389526 on ClinicalTrials.gov